Member Info for Troutisout1

Laura,

Always gave you straight answers you just didn't want to listen.

Still hold a small amount of PYC and still hold 2.99% of FAB, made and took decent profits from PYC and sit on large paper profits in FAB (even better when the PYC profits were used to buy FAB stock after their placing in March).

I am pointing out that it was a £67.5k contract and one of the later stage development projects to date, now when going into a more costly (later stage) phase 2 would you risk using a Company that has not worked in that later stage before?

There are many CROs out there that can accommodate not just all you have said, but organise and oversee the trial, recruit the volunteers, advise and collect data as well as do all the Biometrics and Model simulations needed to garner all the information they need for a phase 2 study positive result

I was thinking more about the Autumn Internationals :o)

KingHomer,

The MSA was put in place in May of this year.

"The project will involve the application of population Pharmacokinetic (PK) modelling techniques using Phase 1 data to inform the Phase 2 study of a small molecule designed to treat rheumatoid arthritis. The project, valued at £67,500, is expected to complete within the next three months and will be the Company's first rheumatoid arthritis project as well as one of the later development stage projects delivered to date.

The Company has also put in place a Master Service Agreement with the client to define and agree broad commercial terms in relation to envisaged further potential projects in the future."

1. £67.5k

2. First RA project

3. One of the later development stage projects delivered to date

As I said a question of scale and experience, there are plenty of other CROs out there capable of doing everything PYC offers in this area and more.

When we next wake up it will be November, what is due this November???

TBH KingHomer, I would think Elevara would be going to a larger CRO for a lot of the work on that trial, yes PYC might get a small piece of it, but they do not offer enough services to cover all the bases.

The problem with PYC is scale, they have none. Yes their expertise might give them a few £100k contracts here and there in their niche area (virtual tumour), but for larger Biometrics and PK/PD modelling there are many others out there that offer far more services to those embarking on the trial route and they will have the economic scale to offer a better deal.

It would seem PYC get contracts that are at best vey lean on the profitability front and this is because they only offer a small piece of the whole. Many other CROs offer far more of that 'whole' and therefore are likely to get the contracts.

What they actually said in the Presentation was "Six late stage (proposal) Business Development Opportunities"

PS then explains that this is where Proposals have been submitted and are under negotiation with clients.

That is not the same as "6 late stage contracts due " as the prospective clients may not take up the proposal, they may put the business elsewhere or may not proceed (note the comments in the presentation about headwinds still strong in the Biotech area).

Again this has nothing to with Physiomics, it is one of Doseme's dosing tools.

To try and conflate this and Physiomics is another falsehood.

You really are funny! You probably didn't listen to the IMC where they stated that the Company were paying for the drilling campaign and then at certain completion points, they invoice Cornwall Council who pay them from the grant funding.

So the company spend the money and then reclaim half of it from the Grant.

The TR1 from RAB (who are the umbrella of the nominee account) shows that they still hold more than they did before the placing earlier this year. It looks like they had backed the placing which was needed to get the grant for all the current drilling as it was a matched grant. They have then used the rise in price to de-risk and take a nice profit from some of those placing shares. They still hold more than they did at the start of this year and they announced the sell through an RNS, they wouldn't have done that if they were still working the sell order, they would have waited and reported after the order was complete.

The fact you claim to have sold out the other day and then immediately started deramping, suggests a bitter taste has been left in your mouth after the doubling again of the SP, your decision to sell out , you own it...

Good buying so far today and rightly so, this should go back to the 20p over the next few weeks as we get closer to OptiMAL launch and I have a sneaky suspicion that very positive NCI news will come before that to sweeten the launch.

It only needs to go a little higher then 12p comes in to view on the chart, the fundamentals seem to back that, but the market may want to see more contracts to prove up that type of valuation. Looks like more buying interest continuing today...

You grasping at straws again Laura? Yesterday you tried to link PYC with grants for early cancer detection, something they don't do and now this.

Desperation abounds...

Must admit to averaging up just before the close, another 300k...

Bassman,

There's no mention because neither Company do anything to detect cancer, they both work further down the line with dosing tools and for Beyond Blood developing a test for people who are suffering from the disease to test their blood count (neutrophils) at home.

Laura knows this, but still tries at every opportunity to mislead others by ramping it and making suggestions that aren't true.

Then others here that know this, stay silent, rather than call it out.

Dodgy link 'not available' TRENCH.

Still no-one going to tell me what Physiomics and Beyond Blood have got to do with the early detection of cancer...

Sometimes the silence from some, after outlandish claims by Laura make you just as complicit in the web of deceit...

Laura, exactly what does Physiomics or Beyond Blood have to do with the early detection of cancer???

"The project is one of 7 innovative pilots backed by a £14 million investment aimed to improve the early detection of cancer"

Actually, I think it will go up quite significantly, when that happens, who knows? But we are getting closer to several catalysts for a re-rate and the jump will come when you least expect it.

Between 9.02am and 9.17am a total of 424k shares were sold and the bid price didn't move, which was very unusual???

Lots of deceit here, the terms of the grant for the drilling were explained in the IMC, £1.52m is being spent on the drill and MRE programme, 50%-50% with the Company and the Prosperity Fund. The Company pay for the drilling programme and the invoice Cornwall Council who then re-imburse them with the grant monies at completed stages.

So no wonder cash was down at the end of September, it will be replenished by 50% payments toward work now completed and this will go on until Q1 when the process is complete.